Atherosclerosis Newswire (Page 2)

Atherosclerosis Newswire (Page 2)

Comprehensive Real-Time News Feed for Atherosclerosis. (Page 2)

Results 21 - 40 of 90 in Atherosclerosis

  1. DNA methylation and atherosclerosis.Read the original story

    Nov 15, 2016 | CiteULike

    ... epigenetic alteration as a distinct and crucial mechanism to regulate genes governing cell proliferation in atherosclerosis has emerged. Aberrant methylation is related to aging, and, because it affects a large number of CpG islands, age-related ...

    Comment?

  2. New statin guidlines issued for primary CVD preventionRead the original story w/Photo

    Nov 14, 2016 | Medical News Today

    ... result in heart attack and stroke , respectively. Statins are a class of medicine commonly used to treat atherosclerosis , a condition where abnormally high levels of cholesterol have led to the building of plaques in the arteries. This can ...

    Comment?

  3. Atherosclerosis Therapeutic and Overview Pipeline Review H2Read the original story

    Nov 13, 2016 | World News Report

    PUNE, INDIA, November 14, 2016 / EINPresswire.com / -- Atherosclerosis is a condition where the arteries become narrowed and hardened due to an excessive buildup of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications.

    Comment?

  4. Treatment of Hyperlipidemia Changes With Level of Kidney Function-Rationale.Read the original story

    Nov 12, 2016 | CiteULike

    ... lipoprotein, and low HDL are associated with aortic pulsewave velocity and other markers of atherosclerosis. Statins are effective in reducing LDL and do decrease risk of cardiovascular events in patients with CKD not requiring dialysis but have no ...

    Comment?

  5. Monocyte Adhesion and Plaque Recruitment During Atherosclerosis...Read the original story

    Aug 24, 2016 | Circulation

    ... NYU School of Medicine, New York (B.R., K.J.M.). Objective- The chronic inflammation associated with atherosclerosis is caused by lipid deposition followed by leukocyte recruitment to the arterial wall. We previously showed that the hematopoietic ...

    Comment?

  6. Dyslipidemia Drugs Market at a CAGR of -10.3% from 2015 to 2023Read the original story w/Photo

    Nov 2, 2016 | SBWire

    Dyslipidemia is a chronic metabolic disease, characterized by abnormal amount of low density lipoprotein, high density lipoprotein and triglyceride levels. Abnormal lipid level is also one of the major risk factor for the cardiovascular diseases such as atherosclerosis, hypertension and others.

    Comment?

  7. Researchers identify two new potential drug targets for treating atherosclerosisRead the original story w/Photo

    Oct 31, 2016 | Medical News

    Researchers at Brigham and Women's Hospital have found two new potential drug targets for treating arterial diseases such as atherosclerosis. By using proteomics to screen a vast number of molecules, the researchers identified PARP9 and PARP14 - two members of the PARP family of proteins - as regulators of macrophage activation, which has been linked to arterial disease by systems biology.

    Comment?

  8. Amazon CEO, Mayo Clinic Back Bay Area Anti-Aging Firm Unity Biotech's $116 Million Funding RoundRead the original story

    Oct 27, 2016 | BioSpace

    ... disease and demonstrates that the selective elimination of senescent cells holds the promise of treating atherosclerosis in humans. In animal models of both early and late disease, the authors show that selective elimination of senescent cells ...

    Comment?

  9. UNITY Biotechnology Raises $116M for Senescent Cell Clearance DevelopmentRead the original story w/Photo

    Oct 27, 2016 | Fight Aging!

    ... disease and demonstrates that the selective elimination of senescent cells holds the promise of treating atherosclerosis in humans. In animal models of both early and late disease, the authors show that selective elimination of senescent cells ...

    Comment?

  10. Jeff Bezos, Mayo Clinic back anti-aging startup Unity Biotechnology for $116 millionRead the original story w/Photo

    Oct 27, 2016 | TechCrunch

    ... It also announced it would be publishing a study in the journal Science about about its work in treating atherosclerosis. That type of traction has perked some of the top investors in science and medicince and is one of the larger private financings ...

    Comment?

  11. Texas Biomed researcher seeks to identify molecular mechanisms underlying early atherosclerosisRead the original story w/Photo

    Oct 25, 2016 | Medical News

    Texas Biomedical Research Institute Staff Scientist Dr. Genesio Karere was recently awarded a $609,568 grant from the National Institutes of Health to study and identify molecular mechanisms underlying early atherosclerosis. Atherosclerosis is a thickening of the walls of arteries caused by high levels of "bad" cholesterol in the blood, which leads to cardiovascular disease and stroke.

    Comment?

  12. Texas Biomed Scientist Awarded NIH Grant to Study Early Onset AtherosclerosisRead the original story

    Oct 25, 2016 | Newswise

    Texas Biomedical Research Institute Staff Scientist Dr. Genesio Karere was recently awarded a $609,568 grant from the National Institutes of Health to study and identify molecular mechanisms underlying early atherosclerosis. Atherosclerosis is a thickening of the walls of arteries caused by high levels of "bad" cholesterol in the blood, which leads to cardiovascular disease and stroke.

    Comment?

  13. Evidence for High Cholesterol to Contribute to OsteoarthritisRead the original story w/Photo

    Oct 25, 2016 | Fight Aging!

    ... like obesity, metabolic syndrome , and diabetes to higher mortality rates. It speeds progression of atherosclerosis , for example, in which fatty deposits build up in blood vessels. The association with osteoarthritis is fairly new, however, and the ...

    Comment?

  14. Europe Atherosclerosis Market and Competitive Landscape Highlights...Read the original story

    Oct 21, 2016 | Customer Interaction Solutions

    This report is classified into nine sections - Atherosclerosis overview including etiology, pathophysiology, and diagnosis, Atherosclerosis treatment options, Atherosclerosis pipeline products, Atherosclerosis market analysis in Europe and by each country. The market analysis comprises of Atherosclerosis epidemiology, key products marketed for Atherosclerosis, market valuations and forecast, products sales and marketshares.

    Comment?

  15. Dr. Jackie R. See M.D. Joins AngioSoma, Inc.'s Scientific Advisory BoardRead the original story w/Photo

    Oct 20, 2016 | Freshnews

    ... but further develop our new patents associated with transdermal skin patches and other methods of treating atherosclerosis, " said Chairman Emeritus Dr. David P. 'Doc' Summers, PhD, FACA. " AngioSoma, Inc. is aggressively adding to its scientific ...

    Comment?

  16. Statins Often Interact With Other Heart DrugsRead the original story w/Photo

    Oct 18, 2016 | MedicineNet

    ... by the U.S. Centers for Disease Control and Prevention. The drugs are prescribed to people who either have atherosclerosis (clogged arteries) or are at risk of it, which means many statin users also take other cardiovascular drugs, the heart ...

    Comment?

  17. Doctors Warn Of Risky Heart Drug CombinationsRead the original story w/Photo

    Oct 18, 2016 | News9 Oklahoma City

    ... by the U.S. Centers for Disease Control and Prevention. The drugs are prescribed to people who either have atherosclerosis (clogged arteries) or are at risk of it, which means many statin users also take other cardiovascular drugs, the heart ...

    Comment?

  18. AngioSoma, Inc. Files 3 New Patent Applications on LiprostinRead the original story w/Photo

    Oct 12, 2016 | Freshnews

    AngioSoma, Inc. filed three new patent applications associated with Liprostina , adding to the Company's product pipeline and supplementing the intellectual property already conveyed by Chairman Emeritus Dr. David P. "Doc" Summers, PhD, FACA. The new patents include transdermal skin patches and other methods of treating atherosclerosis, commonly called Peripheral Artery Disease and Coronary Artery Disease .

    Comment?

  19. AngioSoma Files 3 New Patent Applications on LiprostinRead the original story

    Oct 10, 2016 | BioSpace

    AngioSoma, Inc. filed three new patent applications associated with Liprostina , adding to the Company's product pipeline and supplementing the intellectual property already conveyed by Chairman Emeritus Dr. David P. "Doc" Summers, PhD, FACA. The new patents include transdermal skin patches and other methods of treating atherosclerosis, commonly called Peripheral Artery Disease and Coronary Artery Disease .

    Comment?

  20. Coronary Artery Calcification in Hemophilia A: No Evidence for a...Read the original story

    Mar 1, 2012 | Circulation

    Objective- Ischemic heart disease mortality is lower in hemophilia patients than in the general male population. As coagulation plays a role in the inflammatory pathways involved in atherogenesis, we investigated whether the clotting factor deficiency protects hemophilia patients from developing atherosclerosis.

    Comment?